P&G signals its intent with Merck acquisition
This article was originally published in OTC Bulletin & The Rose Sheet
Procter & Gamble (P&G) is set to acquire for €3.4 billion Merck KGaA’s Consumer Health business, in a move the consumer- goods giant claims will improve significantly its “geographic scale, brand portfolio and category footprint” in the world’s leading OTC markets. Subject to regulatory approvals, the transaction is expected to close by the end of the fourth quarter.
You may also be interested in...
P&G's decision to offload its Haliborange children's supplement line will not lead to reduced competition in the UK market, according to the regulator.
Net and organic sales up 7% to $17.8bn in its FY 2020 Q1 as its turnaround takes hold and pricing increases it implemented a year ago push revenues. CFO Jon Moeller says P&G revises guidance upwards for FY2020 and is better positioned to counter potential recession headwinds than it was in 2008.
Procter & Gamble has been rapped by the UK Advertising Standards Authority for claims made for its recently acquired Seven Seas dietary supplements in a magazine advertisement.